Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
Cancer Cell. 2016 Mar 14;29(3):243-244. doi: 10.1016/j.ccell.2016.02.016.
CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.
CDK4/6 抑制剂已获准用于治疗激素阳性乳腺癌，但其他侵袭性癌症是否对这些分子有反应尚不清楚。在本期《癌细胞》杂志上，Goel 等人（2016 年）报告了 CDK4/6 抑制剂在降低 mTOR 功能和使 HER2 阳性癌症重新对 EGFR/HER2 阻断敏感方面的意外活性。
